Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using finasteride for 4 months and minoxidil for over a year, experiencing significant hair loss and thinning. Others suggest it might be a shedding phase, with some users sharing similar experiences and eventual regrowth, while others express skepticism about the effectiveness of the treatments.

The user shared their 4-month progress using a topical solution of 5% minoxidil and 0.1% finasteride, reporting initial shedding that stopped after 2.5 months and noticeable regrowth, especially in the crown area. They use Glenmark Hair4U F from India and have experienced no side effects.

A user shared their 4-month hair regrowth progress using 0.5mg dutasteride and 2.5mg minoxidil, reporting no side effects and significant improvement. The conversation includes discussions on treatment choices, dosages, and personal experiences with hair loss treatments.

Slow_Class_4465's progress using finasteride and minoxidil to address hair loss, which has resulted in drastic improvement. Other users have shared their experiences with the treatments, including possible side effects.

The user experienced hair regrowth using a chewable combination of oral minoxidil and finasteride without side effects, unlike when taken separately. The treatment is from Hims, and the user is satisfied with the progress, especially on the crown.

User follows a hair loss protocol with topical finasteride, minoxidil, RU58841, stemoxydine, and microneedling. They plan to get a hair transplant at month 9 and ask for opinions on their progress.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

User shared progress after 4 months using topical minoxidil and oral finasteride, reporting noticeable regrowth and no side effects. Other users discussed their experiences and advice on similar treatments, including dutasteride and derma stamping.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

The user shared their 4-month hair loss progress, noting initial hair loss followed by improvement. They used a dermaroller twice a week with varying needle sizes.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

A user reported positive results after four months of using finasteride and topical minoxidil for hair loss, with no side effects. They also use ketoconazole shampoo, dermarolling, and rosemary spray.

A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

The user is experiencing hair regrowth after 4.5 months using 1 mg finasteride daily, 5% minoxidil twice daily, and ketoconazole 2% shampoo. Suggestions include microneedling and possibly a hair transplant for further improvement.

The user experienced good hair growth using topical minoxidil 5% and finasteride for 4 months but lost progress after switching to oral minoxidil and finasteride and shaving their head. They have returned to using topical treatments and are seeking advice on similar experiences.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

The user is using 1mg Finasteride daily and ketoconazole shampoo twice weekly for hair regrowth, with noticeable improvement. They are considering adding Minoxidil to their regimen.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

The conversation is about hair loss treatments, focusing on finasteride and considering a switch to dutasteride due to hairline recession. Users suggest trying minoxidil or dermarolling before switching, while others recommend dutasteride for more aggressive hair loss.